JP2025148380A5 - - Google Patents
Info
- Publication number
- JP2025148380A5 JP2025148380A5 JP2025111263A JP2025111263A JP2025148380A5 JP 2025148380 A5 JP2025148380 A5 JP 2025148380A5 JP 2025111263 A JP2025111263 A JP 2025111263A JP 2025111263 A JP2025111263 A JP 2025111263A JP 2025148380 A5 JP2025148380 A5 JP 2025148380A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- drug conjugate
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305279.6 | 2022-03-11 | ||
| EP22305279 | 2022-03-11 | ||
| PCT/EP2023/056097 WO2023170247A1 (en) | 2022-03-11 | 2023-03-10 | Antibody-drug conjugates and their uses |
| JP2024551627A JP7706668B2 (ja) | 2022-03-11 | 2023-03-10 | 抗体－薬物コンジュゲート及びそれらの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024551627A Division JP7706668B2 (ja) | 2022-03-11 | 2023-03-10 | 抗体－薬物コンジュゲート及びそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025148380A JP2025148380A (ja) | 2025-10-07 |
| JP2025148380A5 true JP2025148380A5 (https=) | 2026-03-24 |
Family
ID=80979142
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024551627A Active JP7706668B2 (ja) | 2022-03-11 | 2023-03-10 | 抗体－薬物コンジュゲート及びそれらの使用 |
| JP2025111263A Pending JP2025148380A (ja) | 2022-03-11 | 2025-07-01 | 抗体－薬物コンジュゲート及びそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024551627A Active JP7706668B2 (ja) | 2022-03-11 | 2023-03-10 | 抗体－薬物コンジュゲート及びそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250302978A1 (https=) |
| EP (1) | EP4489788A1 (https=) |
| JP (2) | JP7706668B2 (https=) |
| KR (1) | KR20240168351A (https=) |
| CN (1) | CN119173279A (https=) |
| AU (1) | AU2023231442A1 (https=) |
| CA (1) | CA3245732A1 (https=) |
| CL (1) | CL2024002655A1 (https=) |
| CO (1) | CO2024012022A2 (https=) |
| CR (1) | CR20240375A (https=) |
| DO (1) | DOP2024000178A (https=) |
| IL (1) | IL314828A (https=) |
| JO (1) | JOP20240199A1 (https=) |
| MX (1) | MX2024011013A (https=) |
| PE (1) | PE20251386A1 (https=) |
| WO (1) | WO2023170247A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240091372A1 (en) * | 2022-07-19 | 2024-03-21 | Seoul National University R&Db Foundation | Anti-doppel antibody drug conjugates |
| AU2024263367A1 (en) | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| EP4534102A1 (en) * | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534101A1 (en) * | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| FR3164899A1 (fr) * | 2024-07-24 | 2026-01-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| CN120737008B (zh) * | 2025-09-04 | 2025-11-11 | 韶远科技（上海)有限公司 | 一种(S)-4-[2-(Boc-氨基)-1-羟基乙基]-2-硝基苯酚及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| EP3423105B1 (en) * | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| BR112020003466B1 (pt) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | Métodos de produção de composto, e, composto |
| JP7423513B2 (ja) * | 2017-09-18 | 2024-01-29 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体α抗体コンジュゲート及びその使用 |
| JP7381478B2 (ja) | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| CN112125915A (zh) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| US20240216525A1 (en) * | 2021-03-30 | 2024-07-04 | Mablink Bioscience | Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties |
-
2023
- 2023-03-10 CR CR20240375A patent/CR20240375A/es unknown
- 2023-03-10 PE PE2024001907A patent/PE20251386A1/es unknown
- 2023-03-10 JP JP2024551627A patent/JP7706668B2/ja active Active
- 2023-03-10 IL IL314828A patent/IL314828A/en unknown
- 2023-03-10 AU AU2023231442A patent/AU2023231442A1/en active Pending
- 2023-03-10 CA CA3245732A patent/CA3245732A1/en active Pending
- 2023-03-10 MX MX2024011013A patent/MX2024011013A/es unknown
- 2023-03-10 CN CN202380039749.4A patent/CN119173279A/zh active Pending
- 2023-03-10 US US18/844,818 patent/US20250302978A1/en active Pending
- 2023-03-10 WO PCT/EP2023/056097 patent/WO2023170247A1/en not_active Ceased
- 2023-03-10 EP EP23710874.1A patent/EP4489788A1/en active Pending
- 2023-03-10 KR KR1020247033958A patent/KR20240168351A/ko active Pending
-
2024
- 2024-09-03 CO CONC2024/0012022A patent/CO2024012022A2/es unknown
- 2024-09-04 CL CL2024002655A patent/CL2024002655A1/es unknown
- 2024-09-11 JO JOJO/P/2024/0199A patent/JOP20240199A1/ar unknown
- 2024-09-11 DO DO2024000178A patent/DOP2024000178A/es unknown
-
2025
- 2025-07-01 JP JP2025111263A patent/JP2025148380A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025148380A5 (https=) | ||
| WO2023078021A1 (en) | Bcma monoclonal antibody and the antibody-drug conjugate | |
| FI116038B (fi) | Menetelmä lysosomaalientsyymillä pilkottavissa olevien kasvaintenvastaisien lääkeainekonjugaattien valmistamiseksi | |
| JP2025510629A (ja) | カンプトテシンコンジュゲート | |
| CN109562170B (zh) | 抗cd98抗体及抗体药物偶联物 | |
| KR20200138759A (ko) | 인간화 항-전립선 특이적 막 항원(psma) 항체 약물 접합체 | |
| BR112019015950A2 (pt) | conjugados de anticorpo anti-ccr7 e fármaco | |
| CA3259758A1 (en) | Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates | |
| CN117279663A (zh) | 一种包括针对人cldn18.2的抗体的抗体药物偶联物及其用途 | |
| CN110582505A (zh) | 吡咯并苯并二氮杂*缀合物 | |
| BR112020008974A2 (pt) | conjugados de ligante-fármaco como substratos para clivagem seletiva pela atividade de exopeptidase da catepsina b | |
| HK1255483A1 (zh) | 抗体和免疫结合物 | |
| CN116157417A (zh) | 抗体-药物缀合物的制造方法 | |
| BR112021011900A2 (pt) | Anticorpos para pmel17 e conjugados dos mesmos | |
| TW202515620A (zh) | 抗體－藥物偶聯物靶向治療前列腺癌和其他腫瘤 | |
| JPWO2021090062A5 (https=) | ||
| CA2902757A1 (en) | Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer | |
| WO2024235130A9 (zh) | 多环化合物及其制备方法和用途 | |
| CN120882432A (zh) | 抗cd70抗体-药物缀合物 | |
| CN120733061A (zh) | 包含抗人trop2的抗体的抗体-药物缀合物及其用途 | |
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| RU2801630C2 (ru) | Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение | |
| EP4534102A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| RU2826228C2 (ru) | Конъюгаты антитело-sting агонист и их применение в иммунотерапии | |
| WO2025214403A1 (zh) | 抗体药物偶联物、组合物及其用途和方法 |